Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results

Key Points

• Quarterly beat: Gain Therapeutics reported EPS of ($0.11), beating consensus by $0.03, while the stock traded down to $1.89 and the company has a market cap of about $72.7M with a negative P/E (-3.10).
• Analyst outlook: The consensus is a Moderate Buy with an average price target of $8.00 (five Buy ratings vs. one Sell), and individual targets ranging up to $10.00.
• Business focus: Gain is a clinical-stage biotech using its AlphaTarget allosteric platform, with lead candidate GT-022 in development for Gaucher disease.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03, FiscalAI reports.

Gain Therapeutics Stock Performance

GANX stock traded down $0.07 during trading on Thursday, reaching $1.89. 472,899 shares of the stock were exchanged, compared to its average volume of 876,248. Gain Therapeutics has a twelve month low of $1.41 and a twelve month high of $4.34. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $72.69 million, a P/E ratio of -3.10 and a beta of -0.03. The stock has a 50 day simple moving average of $2.13 and a 200-day simple moving average of $2.37.

Analysts Set New Price Targets

A number of analysts have recently weighed in on GANX shares. Roth Mkm restated a "buy" rating and issued a $10.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Gain Therapeutics in a research report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Gain Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $8.00.

Institutional Trading of Gain Therapeutics

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of Gain Therapeutics by 2.9% in the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock valued at $523,000 after purchasing an additional 8,251 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company's stock valued at $498,000 after buying an additional 80,407 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Gain Therapeutics during the 3rd quarter valued at about $47,000. Squarepoint Ops LLC bought a new stake in Gain Therapeutics in the third quarter valued at about $68,000. Finally, Virtu Financial LLC raised its position in Gain Therapeutics by 126.9% in the third quarter. Virtu Financial LLC now owns 54,008 shares of the company's stock worth $96,000 after purchasing an additional 30,207 shares in the last quarter. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.